Based on the Gompertzian type of tumor growth, tumors in their initial phases grow rapidly simply because they have a superior growth fraction. Eventually, because the tumor burden increases,its growth plateaus and also the growth fraction decreases.
Growth fraction and tumor burden are thus inversely related. Cell cycle-specific and cell cycle-nonspecific medicine is given in combination, because cell cycle-specific drugs reduce a tumor's growth fraction and cell cycle-nonspecific drugs lessen the tumor burden.
Many antineoplastic agents are dose-limiting due to their overall cytotoxicity. The limits imposed by the toxicities on the different organ systems resulted in using combination drugs to attain better therapeutic outcomes. Combination therapy requires the utilization of two or more drugs highly effective against a tumor type.
The introduction of this tactic is one of the major advances in cancer treatment in the past Two decades. Combination treatments are better than single-drug therapy due to higher tumor response rates and increased amount of remissions.
Many regimens in current use have shown to boost the response rate by 2 to 4 times. Two or more drugs could be given simultaneously or in sequence. The response rates and survival rates are more dramatic simply because they accomplish the next:
To make sure lysis of proliferating and resting cells, combination chemotherapy is run in courses. The amount of courses used in treatment varies depending on the kind of cancer, the chemotherapy agents used, and also the patient's reaction to therapy.
Our website is not responsible for the information contained by this article. Articleinput.com is a free articles resource thus practically any visitor can submit an article. However if you notice any copyrighted material, please contact us and we will remove the article(s) in discussion right away.
Note: This article was sent to us by: Alan Reed at 07252011
1. Monoclonal antibodies and their role in chemotherapy
All articles are property of their respective authors. Please read our Privacy Policy!
© 2009 ArticleInput.com.
Partners: Damenmode